APA (7th ed.) Citation

Mackensen, A., Haanen, J. B., Koenecke, C., Alsdorf, W., Wagner-Drouet, E., Borchmann, P., . . . Şahin, U. (2023). CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: The phase 1 BNT211-01 trial. Nature medicine, 29(11), 2844-2853. https://doi.org/10.1038/s41591-023-02612-0

Chicago Style (17th ed.) Citation

Mackensen, Andreas, et al. "CLDN6-specific CAR-T Cells Plus Amplifying RNA Vaccine in Relapsed or Refractory Solid Tumors: The Phase 1 BNT211-01 Trial." Nature Medicine 29, no. 11 (2023): 2844-2853. https://doi.org/10.1038/s41591-023-02612-0.

MLA (9th ed.) Citation

Mackensen, Andreas, et al. "CLDN6-specific CAR-T Cells Plus Amplifying RNA Vaccine in Relapsed or Refractory Solid Tumors: The Phase 1 BNT211-01 Trial." Nature Medicine, vol. 29, no. 11, 2023, pp. 2844-2853, https://doi.org/10.1038/s41591-023-02612-0.